BlackRock acquired 2.84M Bicara Therapeutics Common Stock shares worth $58M. That's 0.00% of their equity portfolio (2329th largest holding). The investor owns 4.87% of the outstanding Bicara Therapeutics Common Stock stock. The stake costed the investor $36.3M, netting the investor a gain of 60% so far.